Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 3.12 AUD 2.97% Market Closed
Market Cap: 253.5m AUD
Section:
 

Relative Value

The Relative Value of one MYX stock under the Base Case scenario is 10.46 AUD. Compared to the current market price of 3.12 AUD, Mayne Pharma Group Ltd is Undervalued by 70%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MYX Relative Value
Base Case
10.46 AUD
Undervaluation 70%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

0.6
P/S
P/S
Price to Sales
0.6
vs History
76
vs Industry
63
Median 3Y
1.4
Median 5Y
1.1
Industry
2.6
Forward
0.6
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
42
Median 3Y
-2.2
Median 5Y
-2.9
Industry
21.7
Forward
-93.6
More Details
14.5
P/OCF
P/OCF
Price to OCF
14.5
vs History
28
vs Industry
0
Median 3Y
-6.4
Median 5Y
-22.4
Industry
16.7
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-6.8
Median 5Y
-7.1
Industry
23.1
More Details
0.7
P/B
P/B
Price to Book Value
0.7
vs History
53
vs Industry
53
Median 3Y
0.8
Median 5Y
0.7
Industry
2.2
More Details
0.4
EV/S
EV/S
Enterprise Value to Sales
0.4
vs History
76
vs Industry
67
Median 3Y
1
Median 5Y
0.8
Industry
2.9
Forward
0.3
More Details
0.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
0.6
vs History
76
vs Industry
71
Median 3Y
1.5
Median 5Y
1.3
Industry
5.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-4.3
Industry
13.2
Forward
2.6
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.2
Median 5Y
-4.3
Industry
16.8
Forward
-223.6
More Details
8.8
EV/OCF
EV/OCF
Enterprise Value to OCF
8.8
vs History
28
vs Industry
0
Median 3Y
-3.7
Median 5Y
-12.7
Industry
15.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-9
Median 5Y
-21.2
Industry
19.2
More Details
0.2
EV/IC
EV/IC
Enterprise Value to IC
0.2
vs History
90
vs Industry
74
Median 3Y
0.3
Median 5Y
0.4
Industry
1.9
More Details

Multiples Across Competitors

MYX Competitors Multiples
Mayne Pharma Group Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Mayne Pharma Group Ltd
ASX:MYX
253.5m AUD 0.6 -2.7 -2.1 -2.1
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55 36.9 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
496.6B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
259.2B CHF 4.2 27.5 11.7 13.7
UK
AstraZeneca PLC
LSE:AZN
212B GBP 4.9 30.2 108.4 158.6
CH
Novartis AG
SIX:NOVN
208.2B CHF 4.7 18.2 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
251.4B USD 3.9 13.2 9.4 11.2
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
209B USD 90.1 -71.5 331.1 830.4
US
Pfizer Inc
NYSE:PFE
143.2B USD 2.3 14.6 7.4 10.2
P/E Multiple
Earnings Growth PEG
AU
Mayne Pharma Group Ltd
ASX:MYX
Average P/E: 24
Negative Multiple: -2.7 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.5
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.2
38%
0.8
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -71.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.6
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Mayne Pharma Group Ltd
ASX:MYX
Average EV/EBITDA: 438.8
Negative Multiple: -2.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.4
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
331.1
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
1%
7.4
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Mayne Pharma Group Ltd
ASX:MYX
Average EV/EBIT: 1 881.3
Negative Multiple: -2.1 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.6
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.7
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.6
23%
6.9
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11.2
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
830.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
8%
1.3

See Also

Summary
MYX intrinsic value, competitors valuation, and company profile.
DCF Valuation
MYX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
MYX stock valuation using valuation multiples.
Wall Street Estimates
MYX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
MYX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 304,200+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.